This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Canal, P. Articles by Bugat, R. Search for Related Content PubMed PubMed Citation Articles by Canal, P. Articles by Bugat, R.

Plasma and Cellular Pharmacokinetics of Mitoxantrone in High-Dose Chemotherapeutic Regimen for Refractory Lymphomas

Groupe de Pharmacologie Clinique et Expérimentale des Médicaments Anticancéreux, Centre Claudius Regaud, Toulouse, France [P. C., E. C., S. G., G. H., R. B.]; Département d'Hématologie, CHR Purpan, Toulouse, France [M. A., F. H., C. M., D. S., G. L.]; and Université Paul Sabatier, Toulouse, France [E. C., G. L., G. H., R. B.]

We have studied the plasma and peripheral leukocyte pharmacokinetics of mitoxantrone associated, in a high-dose regimen, with cyclophosphamide, carmustine, and etoposide in patients with refractory lymphoma undergoing autologous bone marrow transplantation. Nineteen patients with refractory lymphoma were involved in a clinical trial with escalated doses (15–90 mg/m²) of mitoxantrone administered by 30-min i.v. infusion 8 days before an autologous bone marrow transfusion. Mitoxantrone was measured by high-performance liquid chromatography in plasma and peripheral lymphocytes. The plasma pharmacokinetics of mitoxantrone was linear between 15 and 90 mg/m²: total body clearance (19.3 ± 6.2 liter/h/m²) and volume of distribution at steady state (486 ± 254 liter/m²) were not altered by increasing the dose. The exposure of bone marrow transplant to the plasma residual concentration of mitoxantrone was correlated with the limiting hematological toxicity of the regimen (P < 0.001). At all times, the mitoxantrone concentration in peripheral cells was much higher than in plasma and was retained at a constantly high concentration level. Whereas cellular versus plasma maximum concentration ratio was near 1, the area under the concentration ± time curve ratio reached 100, suggesting a long elimination half-life from cells. Plasma and cellular pharmacokinetics data of mitoxantrone reinforce the idea that this drug is a good candidate for high-dose chemotherapy regimen.

¹ To whom requests for reprints should be addressed, at Centre Claudius Regaud, 20–24 rue du Pont Saint-Pierre, 31052 Toulouse Cedex, France.

Received 6/ 8/93. Accepted 8/11/93.